Literature DB >> 19050678

Chimeric molecules facilitate the degradation of androgen receptors and repress the growth of LNCaP cells.

Yue-Qing Tang1, Bang-Min Han, Xin-Quan Yao, Yan Hong, Yan Wang, Fu-Jun Zhao, Sheng-Qiang Yu, Xiao-Wen Sun, Shu-Jie Xia.   

Abstract

Post-translational degradation of protein plays an important role in cell life. We employed chimeric molecules (dihydrotestosterone-based proteolysis-targeting chimeric molecule [DHT-PROTAC]) to facilitate androgen receptor (AR) degradation via the ubiquitin-proteasome pathway (UPP) and to investigate the role of AR in cell proliferation and viability in androgen-sensitive prostate cancer cells. Western blot analysis and immunohistochemistry were applied to analyse AR levels in LNCaP cells after DHT-PROTAC treatment. Cell counting and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) cell viability assay were used to evaluate cell proliferation and viability after AR elimination in both LNCaP and PC-3 cells. AR was tagged for elimination via the UPP by DHT-PROTAC, and this could be blocked by proteasome inhibitors. Degradation of AR depended on DHT-PROTAC concentration, and either DHT or an ALAPYIP-(arg)(8) peptide could compete with DHT-PROTAC. Inhibition of cell proliferation and decreased viability were observed in LNCaP cells, but not in PC-3 or 786-O cells after DHT-PROTAC treatment. These data indicate that AR elimination is facilitated via the UPP by DHT-PROTAC, and that the growth of LNCaP cells is repressed after AR degradation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19050678      PMCID: PMC3735208          DOI: 10.1038/aja.2008.26

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


  41 in total

1.  Harnessing the ubiquitination machinery to target the degradation of specific cellular proteins.

Authors:  P Zhou; R Bogacki; L McReynolds; P M Howley
Journal:  Mol Cell       Date:  2000-09       Impact factor: 17.970

Review 2.  Post-transcriptional gene silencing across kingdoms.

Authors:  C Cogoni; G Macino
Journal:  Curr Opin Genet Dev       Date:  2000-12       Impact factor: 5.578

3.  The third helix of the Antennapedia homeodomain translocates through biological membranes.

Authors:  D Derossi; A H Joliot; G Chassaing; A Prochiantz
Journal:  J Biol Chem       Date:  1994-04-08       Impact factor: 5.157

4.  Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.

Authors:  P Jaakkola; D R Mole; Y M Tian; M I Wilson; J Gielbert; S J Gaskell; A von Kriegsheim; H F Hebestreit; M Mukherji; C J Schofield; P H Maxwell; C W Pugh; P J Ratcliffe
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

Review 5.  Androgen receptor involvement in the progression of prostate cancer.

Authors:  H Suzuki; T Ueda; T Ichikawa; H Ito
Journal:  Endocr Relat Cancer       Date:  2003-06       Impact factor: 5.678

6.  L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L.

Authors:  A J Barrett; A A Kembhavi; M A Brown; H Kirschke; C G Knight; M Tamai; K Hanada
Journal:  Biochem J       Date:  1982-01-01       Impact factor: 3.857

7.  Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells.

Authors:  Michael E Wright; Ming-Jer Tsai; Ruedi Aebersold
Journal:  Mol Endocrinol       Date:  2003-05-29

Review 8.  Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.

Authors:  Gerald Andriole; Nicholas Bruchovsky; Leland W K Chung; Alvin M Matsumoto; Roger Rittmaster; Claus Roehrborn; David Russell; Donald Tindall
Journal:  J Urol       Date:  2004-10       Impact factor: 7.450

9.  Chemical genetic control of protein levels: selective in vivo targeted degradation.

Authors:  John S Schneekloth; Fabiana N Fonseca; Michael Koldobskiy; Amit Mandal; Raymond Deshaies; Kathleen Sakamoto; Craig M Crews
Journal:  J Am Chem Soc       Date:  2004-03-31       Impact factor: 15.419

10.  Androgen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survival.

Authors:  Qing Yang; Kar-Ming Fung; Wanda V Day; Bradley P Kropp; Hsueh-Kung Lin
Journal:  Cancer Cell Int       Date:  2005-04-06       Impact factor: 5.722

View more
  8 in total

Review 1.  Targeted protein knockdown using small molecule degraders.

Authors:  Kanak Raina; Craig M Crews
Journal:  Curr Opin Chem Biol       Date:  2017-06-09       Impact factor: 8.822

Review 2.  The androgen receptor-targeted proteolysis targeting chimera and other alternative therapeutic choices in overcoming the resistance to androgen deprivation treatment in prostate cancer.

Authors:  Liuxun Li; Jiangli Xu
Journal:  Clin Transl Oncol       Date:  2022-10-06       Impact factor: 3.340

Review 3.  Overcoming Cancer Drug Resistance Utilizing PROTAC Technology.

Authors:  Matthew R Burke; Alexis R Smith; Guangrong Zheng
Journal:  Front Cell Dev Biol       Date:  2022-04-25

Review 4.  Protacs for treatment of cancer.

Authors:  Kathleen M Sakamoto
Journal:  Pediatr Res       Date:  2010-05       Impact factor: 3.756

Review 5.  Protein quality control system in neurodegeneration: a healing company hard to beat but failure is fatal.

Authors:  Deepak Chhangani; Amit Mishra
Journal:  Mol Neurobiol       Date:  2013-02-03       Impact factor: 5.590

Review 6.  Targeted protein degradation: A promise for undruggable proteins.

Authors:  Kusal T G Samarasinghe; Craig M Crews
Journal:  Cell Chem Biol       Date:  2021-05-17       Impact factor: 9.039

7.  Safety and feasibility of platelet rich fibrin matrix injections for treatment of common urologic conditions.

Authors:  Ethan L Matz; Amy M Pearlman; Ryan P Terlecki
Journal:  Investig Clin Urol       Date:  2017-12-21

Review 8.  The PROTAC technology in drug development.

Authors:  Yutian Zou; Danhui Ma; Yinyin Wang
Journal:  Cell Biochem Funct       Date:  2019-01-02       Impact factor: 3.685

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.